CoreAge Rx publishes a current advertised monthly starting figure. Defy’s public patient handout contains historical prices for particular vial amounts. A historical medication-only amount is not a current monthly care package.
This is a comparison of public service information, not a clinical trial of the two providers. CoreAge Rx receives featured commercial placement on this site. We identify the practical differences and missing details without claiming that either company’s preparation is clinically superior.
An online storefront’s starting rate versus a consultation-oriented service with historical vial details. Compare a current, itemized course of care.
Read the price structure before comparing the number
Request a current quote from Defy that includes consultation, testing, medication, and follow-up. Ask CoreAge Rx for the selected plan’s total and any required add-ons. Do not assume an older pharmacy or formulation in a handout is the current one for your state.
A rate per month, a vial price, and an introductory reduction can describe different commitments. Save the final terms for the selected product and compare the same period of care. Our cost guide provides a consistent checklist.
Compare the assessment and follow-up
Defy’s patient document supplies pharmacy and vial detail that can help prepare questions. CoreAge Rx supplies a more visible storefront entry price. Neither presentation tells you, on its own, whether the assessment is right for your health history or whether treatment will help.
Ask who provides the clinical decision, whether additional testing is needed, how questions reach the clinician, and what a refill involves. For remote care, confirm the clinician can treat a patient in your physical location.
Identify the actual medicine
For both providers, request the pharmacy, full ingredient list, concentration, quantity, route, and beyond-use date. Do not assume the products are identical because both pages use the word sermorelin. Additional ingredients or a route change create a different comparison.
Compounded drugs are not FDA-approved. Historical GEREF approval does not approve current compounds, and facility registration does not establish finished-product approval. The pharmacy guide explains how to verify the entities and information involved.
Separate the service choice from the medical choice
A convenient care model and a clear price can make a service easier to use. They do not establish that sermorelin is appropriate for the reason you are seeking help. Ask the clinician which diagnosis or concern is being addressed and what evidence applies to the intended outcome.
The current literature does not let this review rank these platforms by clinical effectiveness. A hormonal response, customer testimonial, or provider research page is not a direct head-to-head comparison of their dispensed preparations.
Questions to bring to both services
What is the total charge and term? Which pharmacy fills this order? What tests and follow-ups are included? How do I obtain help with a reaction or product question? What happens if the clinician does not prescribe or later recommends stopping?
Read the full CoreAge Rx review and Defy Medical review for source-specific details. Use the first-visit checklist to compare the answers. A disclosed featured placement can direct attention to a service; it should not determine your personal clinical decision.
Sources behind this article
Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.
- CoreAge Rx: Sermorelin product pageProvider primary source · Live product page; starting price is not a verified checkout total.
- Defy Medical: Sermorelin patient handoutProvider patient document · Historical vial pricing and pharmacy names; current availability and care fees require confirmation.
- HHS: Telehealth licensing across state linesUS government guidance · Licensure options depend on the patient location and state rules.
- FDA: Risks of compounded drugsUS regulator · Explains lack of FDA approval and the risks of poor-quality compounded preparations.
- FDA: Compounding questions and answersUS regulator · Compounded medicines differ from FDA-approved generic drugs.
- FDA: 2013 GEREF withdrawal determinationFederal Register / FDA · Historical GEREF products were not withdrawn for safety or effectiveness reasons; this does not approve current compounds.
- Endocrine Society: Adult growth hormone deficiencyClinical practice guideline · Diagnosis and treatment of established deficiency; not an endorsement of anti-aging prescribing.
- Endotext: Growth Hormone and AgingExpert clinical evidence review · Separates hormone and body-composition findings from functional outcomes and long-term unknowns.